Validation of a criterion-based screening and triage pathway for adult ADHD: a prospective observational study of safety and operational efficiency
Protracted encephalopathy and subacute combined degeneration associated with chronic nitrous oxide use: a case report
Parsing autism spectrum heterogeneity through fMRI
Nature Neuroscience, Published online: 15 May 2026; doi:10.1038/s41593-026-02269-1
Autism is remarkably heterogeneous, posing a long-standing challenge for linking genetics to brain dynamics. A cross-species study identifies two principal dysconnectivity signatures across 20 mouse models of autism risk, each associated with distinct molecular pathways, and shows analogous connectivity patterns in autistic humans. These results establish a translational framework for biologically grounded fMRI phenotyping.
Retail-Grade Weighted Blanket Effectiveness on ADHD-related Sleep Disturbances (BEAD)
Interventions: Device: Sleep Intervention with weighted device
Sponsors: University Hospital Bispebjerg and Frederiksberg
Not yet recruiting
Online Evaluation of the Diagnostic Accuracy of BlinkLab’s Digital Assessments for Autism
Interventions: Diagnostic Test: BlinkLab Dx1; Behavioral: Retrospective Neurodevelopmental Diagnostic Assessment
Sponsors: Blinklab Limited
Recruiting
Use of Low Doses of Interleukin-2 in Autism Spectrum Disorders
Interventions: Drug: ILT-101 ld-(IL2); Drug: NaCl (0,9%)
Sponsors: Assistance Publique – Hôpitaux de Paris; Iltoo Pharma
Not yet recruiting
Acupuncture Treament in Children With Tic Disorders
Interventions: Other: Acupuncture; Behavioral: Comprehensive Behavioral Intervention for Tics (CBIT)
Sponsors: Meizhou People’s Hospital
Not yet recruiting
Family psychoeducation to support patients with psychotic illness: two-year outcomes from a pre–post longitudinal pilot study
[Comment] How much is enough in ADHD pharmacotherapy?
The evidence base for ADHD pharmacotherapy has answered one question more confidently than any other: whether medications are effective, on average, in reducing core ADHD symptoms. We know that several stimulant and non-stimulant treatments, including methylphenidate, amphetamines, atomoxetine, and guanfacine, improve symptoms at the patient-group level.1 What has remained harder to identify is where titration should stop: the point at which further dose escalation is unlikely to yield meaningful additional benefit and might instead worsen tolerability.

